Showing 4461-4470 of 7516 results for "".
- Profounda Launches Impavido for Visceral, Mucosal and Cutaneous Leishmaniasishttps://practicaldermatology.com/news/profounda-launches-impavido-for-visceral-mucosal-and-cutaneous-leishmaniasis/2458636/Profounda, Inc. launched Impavido (miltefosine) in the United States. Impavido is the first oral treatment for visceral, mucosal and cutaneous leishmaniasis approved by the FDA and the first Rx product launched in the US by Profounda. Although skin sores of cutaneous leishmaniasis (CL) us
- Vitae Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor for Psoriasishttps://practicaldermatology.com/news/vitae-achieves-proof-of-concept-with-first-in-class-roryt-inhibitor-for-psoriasis/2458643/Vitae Pharmaceuticals, Inc. shared positive top-line results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic patients. VTP-43742 is Vitae's wholly owned, first-in-class, orally active RORγt inhibitor with the potential to transform the treatment of multiple a
- InfoRx App from Vivacare Enables Dermatologists to Deliver Personalized Patient Education Resourceshttps://practicaldermatology.com/news/inforx-app-from-vivacare-enables-dermatologists-to-deliver-personalized-patient-education-resources/2458651/Vivacare announced the release of its InfoRx mobile app that enables dermatologists to deliver personalized patient handouts, videos and other skin care resources into the hands of their patients and family members. The service is available to U.S.-based dermato
- Syneron Candela Introducing New Technologies at the 2016 AAD Annual Meetinghttps://practicaldermatology.com/news/syneron-candela-introducing-new-technologies-at-the-2016-aad-annual-meeting/2458664/Syneron Medical Ltd., is launching three new products during the 2016 American Academy of Dermatology (AAD) meeting in Washington, DC. The launches include the new CO2RE Intima sy
- ALASTIN™ Skincare, Inc. Announces New Scientific Advisory Councilhttps://practicaldermatology.com/news/alastin-skincare-inc-announces-new-scientific-advisory-council/2458667/ALASTIN™ Skincare, Inc., announced its new eight-person Scientific Advisory Council. The Council includes: · Vivian Bucay, M.D., Dermatologist, B
- Dermwire's Inside Scoop on Hottest Expected AAD2016 Launcheshttps://practicaldermatology.com/news/dermwires-inside-scoop-on-hottest-expected-aad2016-launches/2458670/The American Academy of Dermatology (AAD)’s annual meeting is the place for skin care companies looking to launch the latest – and hopefully greatest --- innovations or iterations in skin care products and technologies. And the
- Galderma to Begin Two Phase III Restylane Trialshttps://practicaldermatology.com/news/galderma-to-begins-two-phase-iii-restylane-trials/2458679/Galderma is set to initiate a pivotal Phase III trial on Restylane® Lyft for hand augmentation and another that will look to the safety of Restylane® Silk when ad
- WHO: Improved Access to Psoriasis Treatments Neededhttps://practicaldermatology.com/news/who-improved-access-to-psoriasis-treatments-needed/2458685/Key stakeholders including policy makers, physicians and patients must come together to turn the corner on psoriasis, according to the World Health Organization’s (WHO) new Globa
- New Initiative Seeks To Raise Biosimilar Awareness, Accesshttps://practicaldermatology.com/news/new-initiative-to-raise-biosimilar-awareness-access/2458689/The Biosimilars Forum is launching a new biosimilars education initiative. The Partnership for Biosimilars Education and Access will focus on raising awareness and encouraging access to biosimilars in the United States. The Forum
- Endo International Launches New Phase 2b Study of CCH for Cellulitehttps://practicaldermatology.com/news/endo-international-launches-new-phase-2b-study-of-cch-for-cellulite/2458699/A Phase 2b study of collagenase clostridium histolyticum (CCH) for the treatment of as cellulite is about to get started, Endo International plc reports. CCH is intended to target and lyse collagen tethers with the goal of releasing the skin di